Phargentis signs early partnership with Euro-wide generic pharma company for its third major generic product
(March 23, 2022) Phargentis has entered an early license agreement with a major European pharmaceutical company over the third major generic inhaled therapy that Phargentis is developing - an interchangeable version of Fostair® (beclomethasone / formoterol), a best-selling pMDI asthma and COPD treatment with a 2020 turnover of 529 MUSD in Europe. Phargentis CEO Andrea…
Phargentis achieves positive results in pilot PK study of its new generic version of COPD treatment indacaterol/glycopyrronium plus DPI device
Phargentis announces another important milestone in achieving positive results in the clinical pilot study of ‘Glide’, its new generic version of COPD treatment indacaterol/glycopyrronium plus Dry Powder Inhaler. The clinical study demonstrated good comparability between ‘Glide’ and originator product Ultibro®Breezhaler®. Phargentis will now proceed to the next pivotal phase of development, on schedule. Global sales…
Phargentis begins clinical development of early-entry generic version of COPD treatment indacaterol/glycopyrronium and DPI device
(16 December, 2021) Phargentis has begun clinical development of its capsule based DPI (Dry Powder Inhaler) product containing indacaterol/glycopyrronium (85 mcg/43 mcg) designed to be an early-entry, fully interchangeable generic version of the global COPD treatment Ultibro®Breezhaler®. Sales of the treatment exceed 500 MUSD a year. The news follows the recent announcement of the company’s…
First European sales of generic Tiotropium bromide 18 µg DPI, developed by Phargentis
(November 10, 2021) Tiotropium bromide 18 µg Dry Powder Inhaler developed by Phargentis has been launched in Europe. It is the first generic product approved in the EU with precisely the same strength and same delivered dose as Spiriva®Handihaler®, the global first-line treatment for COPD. This generic equivalent has been delivered to the UK, Norway,…
Generic Tiotropium bromide 18 µg DPI, developed by Phargentis, receives approval in 28 European countries
(November 11, 2021) Tiotropium bromide 18 µg Dry Powder Inhaler is the first generic product approved in the EU with the same strength and same delivered dose as Spiriva®Handihaler®, the global first line treatment for COPD – enabling possibility for full reimbursement across the European Union and other key international markets. Developed by Phargentis, it…
This website uses cookies to improve your experience. Further information can be found in the cookie policy. Read MoreAccept
Cookies Policy
Privacy Overview
This website uses cookies to improve your experience while you navigate through the website. Out of these, the cookies that are categorized as necessary are stored on your browser as they are essential for the working of basic functionalities of the website. We also use third-party cookies that help us analyze and understand how you use this website. These cookies will be stored in your browser only with your consent. You also have the option to opt-out of these cookies. But opting out of some of these cookies may affect your browsing experience.
Necessary cookies are absolutely essential for the website to function properly. This category only includes cookies that ensures basic functionalities and security features of the website. These cookies do not store any personal information.
Any cookies that may not be particularly necessary for the website to function and is used specifically to collect user personal data via analytics, ads, other embedded contents are termed as non-necessary cookies. It is mandatory to procure user consent prior to running these cookies on your website.